Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Nobelpharma and Eisai Launch Anticonvulsant Agent Fostoin on Jan. 17
January 17, 2012
- MTPC Licenses Hib Vaccine from Nuron Biotech
January 17, 2012
- 38% of Doctors Will Attend Company-Sponsored Events Only if Transportation, Lodging Costs Are Paid: Survey
January 17, 2012
- 100th Acquisition/License Support Agreement Reached through LSIP Fund
January 17, 2012
- MTPC Issues Apology for Its Researcher’s Arrest on Suspicion of Bodily Harm
January 16, 2012
- President Tamura Says Nichi-Iko to Stop Receiving Marketing Right Transfers of Long-Listed Products
January 16, 2012
- Market for New Oral Anticoagulants Getting Crowded
January 16, 2012
- Sales of DPP-4 Inhibitors on Track to Reach ¥100 Bil. this Fiscal Year
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 16, 2012
- No Clear Road to Distribution Reform; New Drug Premium Hurting Wholesalers’ Business
January 16, 2012
- Research Oriented-companies Shake Up Generics Market with Established Products
January 16, 2012
- Taiyo to Be Core of Teva’s Operations in Japan
January 16, 2012
- Nichi-Iko Will Soon Decide on Independent or Joint PI Trial for Remicade Biosimilar: President Tamura
January 16, 2012
- Otsuka to Focus on CNS Field, Ending Collaboration in Immunology, Inflammation with UCB
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 15, 2012
- Nichi-Iko Posts Record-High Sales, Profits in FY2011
January 13, 2012
- Pfizer to Strengthen Role of Manufacturing Division by Spin-Off, Utilizing Its Formulation Technology
January 13, 2012
- Hisamitsu: Sales Up 1.2% Due to Favorable Performance of Overseas Subsidiaries
January 13, 2012
- Major Dispensing Pharmacies, Intermediary Companies Aggressively Seek M&A
January 12, 2012
- Survey Shows Astellas Website Most Frequently Accessed by Doctors
January 12, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…